The effect of eprosartan on reflex sympathetic activation in sodium restricted patients with essential hypertension.

Journal of the American Society of Hypertension : JASH 20110101

Liquid chromatographic method for the simultaneous determination of eprosartan and hydrochlorothiazide in tablets and human plasma.

Journal of AOAC International 20110101

Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study.

Vascular health and risk management 20110101

[Adjustment of antihypertensive therapy to a generic eprosartan preparation. Results of a non-interventional study].

MMW Fortschritte der Medizin 20101014

Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).

Advances in therapy 20100601

Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction.

European journal of heart failure 20100401

Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.

Biopharmaceutics & drug disposition 20100301

Characterization of a novel impurity in bulk drug eprosartan by ESI/MS(n) and NMR.

Journal of pharmaceutical and biomedical analysis 20100205

Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.

Cardiovascular drugs and therapy 20100201

Development and validation of a high-performance liquid chromatographic method for determination of eprosartan in bulk drug and tablets.

Journal of AOAC International 20100101

Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20091201

Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20090901

Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition.

The Journal of pharmacology and experimental therapeutics 20090601

Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats.

Hypertension (Dallas, Tex. : 1979) 20090501

Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.

Expert review of cardiovascular therapy 20090501

Superoxide dismutase and catalase anti-oxidant activity in leucocyte lysates from hypertensive patients: effects of eprosartan treatment.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20090301

Costs of eprosartan versus diuretics for treatment of hypertension in a geriatric population: an observational, open-label, multicentre study.

Drugs & aging 20090101

[The use of melaxen in combined therapy of arterial hypertension in subjects occupied in assembly line production].

Klinicheskaia meditsina 20090101

Eprosartan: a review of its use in hypertension.

Drugs 20090101

Clinical profile of eprosartan: a different angiotensin II receptor blocker.

Cardiovascular & hematological agents in medicinal chemistry 20081001

Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.

Journal of hypertension 20080801

Effects of eprosartan on mitochondrial membrane potential and H2O2 levels in leucocytes in hypertension.

Journal of human hypertension 20080701

Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans.

British journal of clinical pharmacology 20080601

Spectral and polarographic determination of eprosartan. Kinetic studies of the oxidation of eprosartan using a platinum electrode.

Die Pharmazie 20080601

Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.

Hypertension (Dallas, Tex. : 1979) 20080301

Separation and quantitation of several angiotensin II receptor antagonist drugs in human urine by a SPE-HPLC-DAD method.

Journal of separation science 20080301

Selenosartans: novel selenophene analogues of milfasartan and eprosartan.

Bioorganic & medicinal chemistry letters 20080201

Effectiveness of eprosartan in diabetic hypertensive patients.

European journal of internal medicine 20080101

Comparison of monotherapy versus combination antihypertensive therapy in elderly patients with essential hypertension.

Angiology 20080101

[Effect of antihypertensive drugs of various pharmacological groups on reaction of arterial pressure under conditions of stree testing. Part II. Value of various strategies of potentiation of systemic vasodilatation].

Kardiologiia 20080101

[Effect of eprosartan on thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome].

Klinicheskaia meditsina 20080101

Eprosartan in the primary prevention of cardiac allograft vascular disease: a double-blind prospectively randomized study using intravascular ultrasound.

The Journal of international medical research 20080101

Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.

Expert review of cardiovascular therapy 20071101

Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.

Current medical research and opinion 20071101

Angiotensin blockade with eprosartan: vascular and functional implications.

Current medical research and opinion 20071101

Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.

Current medical research and opinion 20071101

Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?

Current medical research and opinion 20071101

Pharmacokinetics and urinary excretion of eprosartan in Chinese healthy volunteers of different gender.

Die Pharmazie 20071001

An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.

Life sciences 20070802

Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors.

Acta cardiologica 20070801

Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients.

Journal of thrombosis and haemostasis : JTH 20070701

Determination of eprosartan in human plasma and urine by LC/MS/MS.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070615

[Role of the renin-angiotensin system on the sympathetic response induced by the cold pressor test in humans].

Investigacion clinica 20070601

Small artery structure adapts to vasodilatation rather than to blood pressure during antihypertensive treatment.

Journal of hypertension 20070501

Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients.

Fundamental & clinical pharmacology 20070401

Effect of AT(1) angiotensin II receptor antagonists on the sympathetic response to a cold pressor test in healthy volunteers.

American journal of therapeutics 20070101

Eprosartan in secondary prevention of stroke: the economic evidence.

Cardiovascular journal of Africa 20070101

[The effectiveness of eprosartan in patients with chronic glomerulonephritis].

Klinicheskaia meditsina 20070101

[Stress-associated hypertension in the work place: results of the STARLET project].

Deutsche medizinische Wochenschrift (1946) 20061117

[Not all antihypertensive agents protect equally well].

MMW Fortschritte der Medizin 20060817

Validation of a solid phase extraction-high performance liquid chromatographic method for the determination of eprosartan in human plasma.

Journal of chromatography. A 20060630

Effect of eprosartan on the sympathetic response to cold pressor test in healthy volunteers.

Autonomic neuroscience : basic & clinical 20060630

Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?

Stroke 20060601

Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension.

American journal of physiology. Heart and circulatory physiology 20060401

Effects of eprosartan on target organ protection.

Vascular health and risk management 20060301

Morbidity and mortality after stroke--eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).

Stroke 20060201

MOSES raises questions.

Stroke 20060201

Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.

American journal of hypertension 20060201

Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial.

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20060101

[An AT-II blocker in patients with type II diabetes and arterial hypertension].

Klinicheskaia meditsina 20060101

Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?

Nature clinical practice. Neurology 20060101

[Effect of eprosartan on psychophysiological functions of drivers with arterial hypertension].

Kardiologiia 20060101

Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.

Diabetes 20051201

Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.

American journal of physiology. Heart and circulatory physiology 20051001

Peripheral sympatholytic actions of four AT1 antagonists: are they relevant for long-term antihypertensive efficacy?

Journal of hypertension 20051001

Haemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stress.

Journal of hypertension 20051001

Analysis of recent papers in hypertension. An angiotensin receptor blocker is more effective than a calcium channel blocker in secondary stroke prevention.

Journal of clinical hypertension (Greenwich, Conn.) 20050801

Adrenal angiotensin: origin and site of generation.

American journal of hypertension 20050801

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

Stroke 20050601

[Effect of a combination of teveten and prestarium in patients with chronic heart failure].

Georgian medical news 20050601

Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients.

International journal of clinical practice 20050401

Effect of eprosartan on catecholamines and peripheral haemodynamics in subjects with insulin-induced hypoglycaemia.

Clinical science (London, England : 1979) 20050201

Losartan increases bradykinin levels in hypertensive humans.

Circulation 20050125

Eprosartan (Teveten) offers new opportunities to prevent a second stroke.

Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20050101

[Cerebral hemodynamics and endothelium function in patients with cerebrovascular pathology treated by teveten].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20050101

Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.

American journal of nephrology 20050101

Eprosartan: a review of its use in the management of hypertension.

Drugs 20050101

Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade.

The British journal of ophthalmology 20041201

Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension.

Blood pressure. Supplement 20041201

Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.

Journal of the American Society of Nephrology : JASN 20041101

New tools, old challenges: the emerging role of angiotensin receptor blockers in the treatment of the systolic hypertension epidemic.

The Canadian journal of cardiology 20041001

Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.

The Canadian journal of cardiology 20041001

The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.

The Canadian journal of cardiology 20041001

The effect of treatment with eprosartan on pulse pressure: factors predicting response.

The Canadian journal of cardiology 20041001

Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.

Journal of human hypertension 20040901

Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension.

American journal of hypertension 20040901

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.

Hypertension research : official journal of the Japanese Society of Hypertension 20040701

A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.

Japanese heart journal 20040701

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.

Circulation 20040504

[Anti-hypertensive effect of eprosartan in diabetic patients].

Anales de medicina interna (Madrid, Spain : 1984) 20040501

Re: Heusser et al: elevation of sympathetic activity by eprosartan in young male subjects.

American journal of hypertension 20040301

Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease.

Journal of hypertension 20040301

Different prejunctional and postjunctional responses to angiotensin II and AT1-receptor inhibition: influence of maturation.

Journal of cardiovascular pharmacology 20040301

Heat shock treatment protects against angiotensin II-induced hypertension and inflammation in aorta.

Cell stress & chaperones 20040301

Potential renoprotective effects of the angiotensin receptor blocker eprosartan: a review of preliminary renal studies.

Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20040101

[Effect of eprosartan on microcirculation and blood rheology in patients with hypertensive disease].

Kardiologiia 20040101

[Comparison of eprosartan and captopril in left ventricular systolic dysfunction: relation of efficacy to myocardial viability].

Kardiologiia 20040101

[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].

Kardiologiia 20040101

Eprosartan dual action offers clinical benefit for elderly and overweight hypertensives.

Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20040101

Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.

Drugs under experimental and clinical research 20040101

Teveten (eprosartan) reduces future risk in hypertensive stroke patients.

Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20040101

[Elevation pressure in morning hours in patients with essential hypertension: effect therapy with eprosartan for leading stress tests].

Kardiologiia 20040101

Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension.

Journal of hypertension 20031201

Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20031201

[Dosage equivalents of AT1-receptor antagonists available in Germany].

Deutsche medizinische Wochenschrift (1946) 20031031

[Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology].

Orvosi hetilap 20030907

AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.

Autonomic neuroscience : basic & clinical 20030829

Elevation of sympathetic activity by eprosartan in young male subjects.

American journal of hypertension 20030801

[When the goal values are more than 20/10 mmHg distant. High blood pressure is to be forced down from two sides immediately].

MMW Fortschritte der Medizin 20030710

Cardiology patient page. Angiotensin receptor blockers.

Circulation 20030624

Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.

Journal of medicinal chemistry 20030605

Pre- and postsynaptic inhibitory potencies of the angiotensin AT1 receptor antagonists eprosartan and candesartan.

European journal of pharmacology 20030523

Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.

Journal of medicinal chemistry 20030227

Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension.

Hypertension (Dallas, Tex. : 1979) 20030201

Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress.

Kidney international 20030201

Eprosartan for the treatment of hypertension.

Expert opinion on pharmacotherapy 20030101

Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure.

British journal of pharmacology 20030101

[Neurocirculatory dystonia (does this disease exist?)].

Kardiologiia 20030101

[Antihypertensive treatment with eprosartan mesilate of patients in acute and late periods of ischemic stroke].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20030101

Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.

The Canadian journal of cardiology 20021201

Clinical profile of eprosartan.

Cardiovascular drugs and therapy 20021201

Drug points: Dysgeusia and burning mouth syndrome by eprosartan.

BMJ (Clinical research ed.) 20021130

Prejunctional and postjunctional inhibitory actions of eprosartan and candesartan in the isolated rabbit mesenteric artery.

Journal of cardiovascular pharmacology 20020701

Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension.

American journal of hypertension 20020701

[Therapy of hypertension. Why the systolic value is decisive].

MMW Fortschritte der Medizin 20020606

AT1 blockers and uric acid metabolism: are there relevant differences?

Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20020601

The clinical profile of the angiotensin II receptor blocker eprosartan.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20020601

[Irbesartan: a new possibility in the treatment of hypertension].

Orvosi hetilap 20020526

Structure elucidation and conformational properties of eprosartan, a non peptide angiotensin II AT1 antagonist.

Journal of pharmaceutical and biomedical analysis 20020401

The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.

The Journal of pharmacology and experimental therapeutics 20020401

Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.

Kidney international 20020401

Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation).

The American journal of cardiology 20020315

Brain angiotensinergic mediation of enhanced water consumption in lactating rats.

American journal of physiology. Regulatory, integrative and comparative physiology 20020301

Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension.

Journal of human hypertension 20020301

Application of capillary zone electrophoresis to the screening of some angiotensin II receptor antagonists.

Electrophoresis 20020101

[Significance of pharmacological blockade of angiotensin II type I receptors for correction of abnormal 24-hour blood pressure profile depending on its variability in patients with arterial hypertension stage II].

Terapevticheskii arkhiv 20020101

Eprosartan: an angiotensin-II receptor antagonist for the management of hypertension.

Heart disease (Hagerstown, Md.) 20020101

Safety and tolerability of eprosartan in combination with hydrochlorothiazide.

Drug safety 20020101

[Policy of antihypertensive therapy in arterial hypertension in the elderly. II].

Klinicheskaia meditsina 20020101

[Effect of eprosartan on left ventricular diastolic function and cerebral hemodynamics in patients with hypertension].

Kardiologiia 20020101

[Metabolic effects of angiotensin-II receptor blockers].

Kardiologiia 20020101

Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan.

Journal of hypertension 20011201

Intrarenal angiotensin II: interstitial and cellular levels and site of production.

Kidney international 20011201

Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension.

Journal of human hypertension 20011201

Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo.

Journal of human hypertension 20011201

Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension.

American journal of hypertension 20011201

Angiotensin II antagonists in systolic blood pressure control.

Hospital medicine (London, England : 1998) 20011201

Differentiation in the angiotensin II receptor 1 blocker class on autonomic function.

Current hypertension reports 20010901

Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure.

Current hypertension reports 20010901

Issues in hypertension: drug tolerability and special populations.

American journal of hypertension 20010701

Pharmacology and clinical efficacy of angiotensin receptor blockers.

American journal of hypertension 20010701

Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.

Cardiovascular research 20010601

Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists.

Bioorganic & medicinal chemistry 20010601

[Antihypertensive drug. Dual action lowers blood pressure more effectively].

MMW Fortschritte der Medizin 20010503

ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.

American heart journal 20010501

Differential effects of eprosartan and losartan at prejunctional angiotensin II receptors.

Naunyn-Schmiedeberg's archives of pharmacology 20010501

Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization.

Molecular pharmacology 20010401

Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.

Postgraduate medicine 20010401

[Stress-induced hypertension. The work site--a cardiovascular risk].

MMW Fortschritte der Medizin 20010315

Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor?

Cleveland Clinic journal of medicine 20010301

Subcellular localization of angiotensin II in kidney and adrenal.

Journal of hypertension 20010301

Central inhibition of AT1receptors by eprosartan--in vitro autoradiography in the brain.

Pharmacological research 20010301

[Angiotensin receptor blockers--significance for the therapy of hypertension].

Wiener medizinische Wochenschrift (1946) 20010101

Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.

Current medical research and opinion 20010101

Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial.

Blood pressure 20010101

Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group.

Blood pressure 19990101

Characterization of [3H]SK&F 108566 as a radioligand for angiotensin type-1 receptor.

Journal of receptor research 19930101

Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566.

The Journal of pharmacology and experimental therapeutics 19920101